Clinical trials: Prostate Cancer Stage
High-risk Prostate Cancer
Conventional Versus Hypofractionated Radiation in High Risk Prostate Patients
Hypofractionated regimen in high-risk prostate cancer will allow the investigators to deliver higher biological doses to targets in order to improve tumor control and with acceptable rectal toxicity compared to conventional…
- Trial name
- CHIRP (NCT01488968)
- Testing
- Standard Radiation Treatment, Hypofractionated radiation treatment
- Where
- Canada
- Volunteers
- 111 people
- Sponsor
- AHS Cancer Control Alberta
Prostate Cancer
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
The purpose of this study is to evaluate the safety of an investigational DNA vaccine, pTVG-HP, a plasmid DNA encoding human prostatic acid phosphatase (PAP), in combination with nivolumab, and the efficacy of this combination in…
- Trial name
- NCT03600350
- Testing
- pTVG-HP, Nivolumab, GM-CSF
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Wisconsin, Madison
Nonmalignant Neoplasm, Prostate Cancer
Lycopene in Treating Patients With Prostate Cancer or Benign Prostatic Hyperplasia
RATIONALE: Chemoprevention is the use of certain substances to keep cancer from forming, growing, or coming back. Eating a diet high in lycopene, a substance found in tomatoes and tomato products, may keep cancer from forming or…
- Trial name
- NCT00416390
- Testing
- lycopene, laboratory biomarker analysis, biopsy
- Volunteers
- 120 people
- Sponsor
- University of Illinois Chicago
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Health Literacy in Understanding Radiation Therapy Information in Patients Undergoing Definitive Radiation Therapy
This study assesses the health literacy and understanding of radiation therapy information during consultation in patients with prostate or breast cancer undergoing definitive radiation therapy.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04927559
- Testing
- Survey Administration
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Southern California
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Prostate Cancer
Comparison Study of PET/CT or PET/MRI Imaging to Magnetic Resonance Imaging (MRI) Alone in Men With Prostate Cancer
This is a study primarily comparing Magnetic Resonance Imaging (MRI) alone to Positron Emission Tomography (PET)/MRI using an experimental tracer, 68Ga-PSMA-HBED-CC, among men with prostate cancer or prostatic cancer…
- Trial name
- NCT03439033
- Testing
- PET/MRI with Gallium-68 labeled PSMA-HBED-CC, Multiple PET/MRI with Gallium-68 labeled PSMA-HBED-CC, PET/CT with Gallium-68 labeled PSMA-HBED-CC
- Where
- United States
- Volunteers
- 273 people
- Sponsor
- Weill Medical College of Cornell University
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
The purpose of this study is to evaluate the efficacy and safety of SL-T10 and GX-I7 or SL-T10, GX-I7 and pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT06344715
- Testing
- SL-T10, GX-I7, Pembrolizumab
- Where
- South Korea
- Volunteers
- 78 people
- Sponsor
- SL VAXiGEN
Metastatic Castration Resistant Prostate Cancer
Combination Study of AZD5069 and Enzalutamide.
ACE is a multi-centre proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate cancer(mCRPC).
- Trial name
- ACE (NCT03177187)
- Testing
- AZD5069, Enzalutamide 40 MG
- Where
- 4 sites in Switzerland, United Kingdom
- Volunteers
- 30 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Adenocarcinoma of the Prostate, Stage I Prostate Cancer
Lycopene in Treating Patients Undergoing Radical Prostatectomy for Prostate Cancer
This randomized phase II trial studies how well different doses of lycopene work in treating patients undergoing radical prostatectomy for prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer
- Trial name
- NCT00450749
- Testing
- therapeutic conventional surgery, laboratory biomarker analysis, lycopene
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
IG-VMAT for Localized Prostate Cancer
To determine if hypofractionated IG-VMAT (70 Gy in 28 fractions over 5.6 weeks) will result in disease-free survival (DFS) that is no worse than DFS following conventionally fractionated IG-VMAT (80Gy in 40 fractions over 8…
- Trial name
- NCT02934685
- Testing
- hypofraction, convention
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Hospital
Prostatic Neoplasm
An Open Label Phase II Study of Biweekly Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Prostatic Adenocarcinoma
Study of Biweekly Docetaxel plus Androgen-Deprivation Therapy (ADT) in Patients with Previously-Untreated, Metastatic, Prostatic Adenocarcinoma
- Trial name
- NCT03061643
- Testing
- Docetaxel, Androgen-Deprivation Therapy (ADT)
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Samsung Medical Center
Prostate Adenocarcinoma, Stage I Prostate Cancer
Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer
This randomized phase II trial studies cholecalciferol and genistein compared to placebo in treating patients with early stage prostate cancer.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT01325311
- Testing
- Cholecalciferol, Genistein, Laboratory Biomarker Analysis
- Where
- 11 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy
The purpose is to see how quickly two different types of prostate cancer participants respond when taking enzastaurin. Cohort 1 - asymptomatic participants with androgen-independent prostate-specific antigen (PSA)-progressive…
- Trial name
- NCT00428714
- Testing
- enzastaurin
- Where
- 11 sites in United States
- Volunteers
- 73 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma
Positron emission tomography (PET) imaging evaluation in men with recurrent prostate cancer to select patients who may benefit from directed therapy
- Trial name
- NCT01304485
- Testing
- Sodium Acetate C11
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Phoenix Molecular Imaging
Genitourinary Cancer, Adrenocortical Carcinoma
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies among four cohorts, bladder or upper tract carcinoma with variant histology, adrenocortical carcinoma, other rare…
- Conditions
- Genitourinary Cancer, Adrenocortical Carcinoma, Non-urothelial Bladder, Non-urothelial Upper Tract
- Trial name
- NCT03333616
- Testing
- Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 100 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
A Study of PSMA ADC in Subjects With Metastatic Castration-resistant Prostate Cancer (mCRPC)
PSMA ADC 2301 is a Phase 2, open-label, study to assess the anti-tumor activity and tolerability of Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC) in two groups of subjects with metastatic…
- Trial name
- NCT01695044
- Testing
- PSMA ADC
- Where
- 36 sites in United States
- Volunteers
- 119 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Prostate Cancer
Feasibility and Safety Study Using Preoperative High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy at High-Risk for Extraprostatic Cancer
This study is being done to test the safety of a single high-dose of radiation therapy before radical prostatectomy (removal of the prostate).
- Trial name
- NCT01163448
- Testing
- High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Non Castrate Metastatic Prostate Cancer
Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer
To determine the maximum-tolerated dose (MTD) of BKM120 when administered orally in combination with daily bicalutamide and LH-RH agonists to men with non castrate metastatic prostate cancer.
- Trial name
- NCMPC-BKM (NCT02487823)
- Testing
- BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Institut Paoli-Calmettes
Prostate Cancer
Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance
This study will evaluate the safety and efficacy of a prostate cancer vaccine named Proscavax (Prostate-specific antigen(PSA) / Interleukin-2(IL-2) / Granulocyte-macrophage colony-stimulating factor(GM-CSF)) in patients with…
- Trial name
- NCT03579654
- Testing
- Proscavax
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- OncBioMune Pharmaceuticals
Prostate Cancer, Castrate Sensitive Prostate Cancer
Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)
The purpose of this study is to assess the safety and effectiveness of radiation therapy with hormone therapy (ADT) and chemotherapy as an investigational study treatment for prostate cancer.
- Conditions
- Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease
- Trial name
- NCT04748042
- Testing
- Abiraterone, Prednisone, External Beam Radiotherapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Michigan Rogel Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.